| Maureen M Lynch, MD | |
|
75 Mount Auburn St, Cambridge, MA 02138-4960 | |
| (617) 496-9506 | |
| Not Available |
| Full Name | Maureen M Lynch |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 75 Mount Auburn St, Cambridge, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033211222 | NPI | - | NPPES |
| E05319 | Other | MA | BC/BS OF MASS |
| 043680 | Other | MA | TUFTS HEALTH PLAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 43680 (Massachusetts) | Primary |
| Entity Name | Children's Hospital Pediatric Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457306664 PECOS PAC ID: 3476541830 Enrollment ID: O20040504000964 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.
Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.
Researchers using the world's largest twin registry to study seven autoimmune diseases found the risk of developing the seven diseases is largely inherited, but that some diseases are more closely related than others.
During pregnancy, the mother supplies the fetus with nutrients and oxygen via the placenta. If placental development is impaired, this may lead to growth disorders of the embryo or to life-threatening diseases of the mother such as preeclampsia, a serious condition involving high blood pressure and increased urinary protein excretion.
› Verified 3 days ago
| Entity Name | Mt Auburn Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992750996 PECOS PAC ID: 6103725031 Enrollment ID: O20040527001374 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.
Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.
Researchers using the world's largest twin registry to study seven autoimmune diseases found the risk of developing the seven diseases is largely inherited, but that some diseases are more closely related than others.
During pregnancy, the mother supplies the fetus with nutrients and oxygen via the placenta. If placental development is impaired, this may lead to growth disorders of the embryo or to life-threatening diseases of the mother such as preeclampsia, a serious condition involving high blood pressure and increased urinary protein excretion.
› Verified 3 days ago
| Entity Name | Chmc Surgical Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902977515 PECOS PAC ID: 7012016488 Enrollment ID: O20070626000304 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.
Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.
Researchers using the world's largest twin registry to study seven autoimmune diseases found the risk of developing the seven diseases is largely inherited, but that some diseases are more closely related than others.
During pregnancy, the mother supplies the fetus with nutrients and oxygen via the placenta. If placental development is impaired, this may lead to growth disorders of the embryo or to life-threatening diseases of the mother such as preeclampsia, a serious condition involving high blood pressure and increased urinary protein excretion.
› Verified 3 days ago
| Entity Name | Chmc Surgical Gynecology Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295360824 PECOS PAC ID: 2365866803 Enrollment ID: O20200716003747 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.
Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.
Researchers using the world's largest twin registry to study seven autoimmune diseases found the risk of developing the seven diseases is largely inherited, but that some diseases are more closely related than others.
During pregnancy, the mother supplies the fetus with nutrients and oxygen via the placenta. If placental development is impaired, this may lead to growth disorders of the embryo or to life-threatening diseases of the mother such as preeclampsia, a serious condition involving high blood pressure and increased urinary protein excretion.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maureen M Lynch, MD 75 Mount Auburn St, Cambridge, MA 02138-4960 Ph: (617) 495-4172 | Maureen M Lynch, MD 75 Mount Auburn St, Cambridge, MA 02138-4960 Ph: (617) 496-9506 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.
Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.
Researchers using the world's largest twin registry to study seven autoimmune diseases found the risk of developing the seven diseases is largely inherited, but that some diseases are more closely related than others.
During pregnancy, the mother supplies the fetus with nutrients and oxygen via the placenta. If placental development is impaired, this may lead to growth disorders of the embryo or to life-threatening diseases of the mother such as preeclampsia, a serious condition involving high blood pressure and increased urinary protein excretion.
› Verified 3 days ago
Emily Rachel Chen, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 2067 Massachusetts Ave, Cambridge, MA 02140 Phone: 617-575-5550 | |
Dr. Laura Need, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 330 Mount Auburn St, Newborn Services, Cambridge, MA 02138 Phone: 617-499-5595 Fax: 617-499-5103 | |
Robert M Meyer, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 119 Windsor St, Cambridge, MA 02139 Phone: 617-665-3646 | |
Lemuel Becker Hewes, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 250 Massachusetts Ave, Cambridge, MA 02139 Phone: 617-417-8678 | |
Michelle Dorrell, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 75 Mount Auburn St, Harvard University Health Services, Dept Of Pediatrics, Cambridge, MA 02138 Phone: 617-495-4171 | |
Dr. Tracy Lynn Mcgregor, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 300 Third St, Cambridge, MA 02142 Phone: 617-551-8200 |